Remember me
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
by
Dmitry L. Maslov 1,*
, 
Oxana P. Trifonova 1, Steven Lichtenberg 2, 
Elena E. Balashova 1, Zaman Z. Mamedli 3, Aleksandr A. Alferov 3, Ivan S. Stilidi 3, 
Petr G. Lokhov 1, Nikolay E. Kushlinskii 3 and Alexander I. Archakov 1
1
Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, 119121 Moscow, Russia
2
Metabometrics Inc., 651 N Broad Street, Suite 205 #1370, Middletown, DE 19709, USA
3
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, 115478 Moscow, Russia
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(1), 140; https://doi.org/10.3390/cancers15010140 (registering DOI)
Received: 29 September 2022 / Revised: 23 December 2022 / Accepted: 24 December 2022 / Published: 26 December 2022
Simple SummaryRenal cell carcinoma (RCC) is one of the most common cancer types. However, the lack of clinical symptoms and validated biomarkers for early stage RCC prevent timely disease diagnosis. The study was focused on revealing potential low molecular biomarkers for early-stage RCC. The untargeted direct injection mass spectrometry-based metabolite profiling of blood plasma samples from non-cancer volunteers (control) and RCC patients (early stages of clear cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chrRCC), and advanced stages of ccRCC) was performed. A set of metabolites with diagnostic power for the early stages of ccRCC was detected.
AbstractEarly diagnostics significantly improves the survival of patients with renal cell carcinoma (RCC), which is the prevailing type of adult kidney cancer. However, the absence of clinically obvious symptoms and effective screening strategies at the early stages result to disease progression and survival rate reducing. The study was focused on revealing of potential low molecular biomarkers for early-stage RCC. The untargeted direct injection mass spectrometry-based metabolite profiling of blood plasma samples from 51 non-cancer volunteers (control) and 78 patients with different RCC subtypes and stages (early stages of clear cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chrRCC) and advanced stages of ccRCC) was performed. Comparative analysis of the blood plasma metabolites between the control and cancer groups provided the detection of metabolites associated with different tumor stages. The designed model based on the revealed metabolites demonstrated high diagnostic power and accuracy. Overall, using the metabolomics approach the study revealed the metabolites demonstrating a high value for design of plasma-based test to improve early ccRCC diagnosis.
Share and CiteMDPI and ACS Style
Maslov, D.L.; Trifonova, O.P.; Lichtenberg, S.; Balashova, E.E.; Mamedli, Z.Z.; Alferov, A.A.; Stilidi, I.S.; Lokhov, P.G.; Kushlinskii, N.E.; Archakov, A.I. Blood Plasma Metabolome Profiling at Different Stages of Renal Cell Carcinoma. Cancers 2023, 15, 140. https://doi.org/10.3390/cancers15010140
AMA StyleMaslov DL, Trifonova OP, Lichtenberg S, Balashova EE, Mamedli ZZ, Alferov AA, Stilidi IS, Lokhov PG, Kushlinskii NE, Archakov AI. Blood Plasma Metabolome Profiling at Different Stages of Renal Cell Carcinoma. Cancers. 2023; 15(1):140. https://doi.org/10.3390/cancers15010140
Chicago/Turabian StyleMaslov, Dmitry L., Oxana P. Trifonova, Steven Lichtenberg, Elena E. Balashova, Zaman Z. Mamedli, Aleksandr A. Alferov, Ivan S. Stilidi, Petr G. Lokhov, Nikolay E. Kushlinskii, and Alexander I. Archakov. 2023. "Blood Plasma Metabolome Profiling at Different Stages of Renal Cell Carcinoma" Cancers 15, no. 1: 140. https://doi.org/10.3390/cancers15010140
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here. Article Metrics Article Access Statistics For more information on the journal statistics, click here.Multiple requests from the same IP address are counted as one view.
Comments (0)